Published online Sep 16, 2015. doi: 10.12998/wjcc.v3.i9.774
Peer-review started: April 22, 2015
First decision: May 19, 2015
Revised: July 8, 2015
Accepted: July 24, 2015
Article in press: July 27, 2015
Published online: September 16, 2015
Processing time: 146 Days and 18.5 Hours
Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory neuroepithelium. ENB constitutes only 3% of all malignant intranasal neoplasm. Because of the rarity, the number of patients of ENB treated in individual departments is small. Most of these patients presents in locally advanced stages and require multimodality treatment in form of surgery, chemotherapy and radiotherapy. Multimodality approach with a risk-adapted strategy is required to achieve good control rates while minimizing treatment related toxicity.
Core tip: This article is a comprehensive review of literature of a rare and aggressive neoplasm. This article outlines the various newer details of diagnosis, staging and treatment aspects of esthesioneuroblastoma (ENB). The importance of multimodality approach in management of ENB is reviewed in detail.